Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Pioneer of a new imaging diagnostic paradigm

We are transforming the imaging diagnostic world by developing the most accurate AI-powered digital biomarkers across multiple imaging modalities. Our focus is to achieve accurate early diagnosis to improve patient lives by helping radiologists and clinicians in their diagnostic workflow in oncology and metabolic diseases.

iBiopsy®

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Median's latest news

We were happy to welcome a large audience during our webcast on Oct. 26th, 2022. The opportunity for Fredrik Brag, CEO and founder of Median, to share the company’s news and prospects and respond to the many questions from participants. The webcast recording is now available!

Watch video

Latest press releases

22 November 2022

Median Technologies fera trois présentations lors de la conférence annuelle du RSNA qui se tiendra du 27 novembre au 1er décembre prochain à Chicago, Etats-Unis

Median Technologies (ALMDT) annonce aujourd’hui que la société participera à la plus grande conférence au monde d’imagerie médicale, la conférence annuelle du RSNA (Radiological Society of North America) qui se tiendra à Chicago, Etats-Unis, du 27 novembre au 1er décembre 2022. La société y fera une présentation industrielle et deux présentations scientifiques.

22 November 2022

Median Technologies to speak at the RSNA 2022 Annual Meeting, Nov. 27 – Dec 1, Chicago, IL, USA, with three presentations

Median Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the 2022 Radiological Society of North America (RSNA) Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 27 – Dec. 1. The Company will give an industry presentation and two scientific presentations.

20 October 2022

Median Technologies communique ses résultats semestriels 2022 et son niveau d’activité pour le troisième trimestre 2022

Au 30 septembre 2022 : Chiffre d’affaires cumulé à 18,7 m€, carnet de commandes à 62,5 m€, trésorerie à 25,9 m€. Très forte traction avec le lancement d’Imaging Lab pour l’activité iCRO, et interactions avancées avec la FDA pour l’étude clinique pivot du logiciel dispositif médical iBiopsy® LCS CADe/CADx.

20 October 2022

Median Technologies announces its 2022 half-year results and revenues for the third quarter

As of Sep. 30, 2022: Total revenues of €18.7 million, Order backlog of €62.5 million, Cash of €25.9 million. Very strong traction with the launch of Median’s Imaging Lab for the iCRO activity and advanced interactions with the FDA for the iBiopsy® LCS CADe/CADx SaMD clinical pivotal study.

3 October 2022

Median Technologies announces formation of Clinical Advisory Board for iBiopsy® Lung Cancer Screening

The Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer and will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy® LCS AI/ML tech-based CADe/CADx Software as Medical device.

1/5

Our Winter Corporate Newsletter

We are pleased to share with you our latest Corporate Newsletter, presenting our most recent announcements. Click below to read the Newsletter!

Webinars

JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges.

The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. Want to know more? Register now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median